CD8A and neoplasm: The first legumain-based DNA vaccine was developed in 2006 and was shown to induce a marked CD8+ T cell response by reducing tumor TAMs density and their release of proangiogenic factors, and subsequently the suppression of tumor growth, angiogenesis, and metastasis [143].